Pilot Study to Evaluate the Safety and the Efficacy of the Matrix and Cells Obtained by the AmeaCell® Device and Intended for the Filling of Wrinkles on the Face.
NCT ID: NCT03529292
Last Updated: 2021-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
23 participants
INTERVENTIONAL
2018-07-09
2021-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a mono-center, pilot study in 24 subjects
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Matrix and Cells obtained by the AmeaCell® device
AmeaCell
Lipoaspirate obtained from liposuction is treated by the AmeaCell® device in order to obtain Matrix and Cells which contains cellular phase and matrix phase. The Matrix ancd Cells are injected in the same patient as facial wrinkles filler.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AmeaCell
Lipoaspirate obtained from liposuction is treated by the AmeaCell® device in order to obtain Matrix and Cells which contains cellular phase and matrix phase. The Matrix ancd Cells are injected in the same patient as facial wrinkles filler.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject wishing liposuction
* Subject wishing a filling of facial wrinkles for aesthetic purposes
* Subject for which it is possible to achieve a puncture of adipose tissue of at least 150ml so that after decantation or centrifugation there remains 100ml of adipose tissue
* Facial wrinkles that can be treated with the Matrix and Cells volume of approximately 12ml
* Grade of wrinkles at level 2 minimum of the nasolabial fold according to the WSRS scale
* Free, informed and written consent
* Affiliate or beneficiary of a social security scheme
Exclusion Criteria
* Woman of childbearing age without effective contraceptive
* Subject having a filling of facial wrinkles with hyaluronic acid or by a method of lipofilling (injection of adipose tissue) in the 12 months prior to the enrollment
* Subject who has undergone treatment of facial wrinkles by injection of botulinum toxin, by mesotherapy or cosmetic procedure (laser, photo modulation, intense pulsed light, radio frequency, dermabrasion, chemical peel or other ablative procedures) within 12 months at least prior to enrolment or subject who is planning this type of procedure during the study
* Subject who has received semi-permanent dermal fillers or permanent facial implants or who is planning to do this type of implant during the study
* Subject having history of formation of hypertrophic scars or keloids
* Subject having a skin disease or skin inflammation (e.g. acne, herpes, eczema, psoriasis, sclerosis) at the site to be treated or elsewhere on the body if suspected of spreading on the site to be treated
* Subject with allergic contact dermatitis or a history of allergic contact dermatitis or a family history of allergic contact dermatitis
* Presence of tattoo and / or scar in the treatment area that, in the opinion of the investigator, could interfere with the evaluation of the study
* Diabetes (type I or type II)
* Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) seropositivity
* Subject under anti-HIV treatment
* Autoimmune disease
* Immunodepression
* History of phlebitis or pulmonary embolism
* Major pathology involving the renal, hepatic, cardiovascular, immune and / or nervous system
* Cancerous lesion on the face
* Any other diseases that could, in the opinion of the investigator, be clinically significant and make the subject inappropriate for the study, alter the results of the study or increase the risk for the subject
* Known hypersensitivity to cobalt
* Known hypersensitivity to collagenase
* Known or suspected allergy to lidocaine or any other amide anesthetic
* History of known severe allergies (anaphylaxis, angioedema) for a product used in the study
* Any contraindication to lipofilling surgery
* Active smoking or subject who stopped smoking less than one month before the intervention
* Radiotherapy treatment at the head and neck region.
* Chemotherapy treatment
* Treatment with anticoagulant or Nonsteroidal anti-inflammatory drug (NSAID) or any other substance known to increase clotting time during the 2 weeks prior to enrollment
* Corticosteroids in the 6 weeks prior to enrollment
* Subject having a metal-metal hip prosthesis
* Subject under lidocaine or structurally related local anesthetic (e.g. bupivacaine) within 24 hours prior to enrollment
* Subject having undergone general anesthesia for less than 8 days
* Treatment with an oral or topical retinoid in the month prior to enrollment
* Subject having a history of drug or alcohol addiction in the 12 months prior to enrollment
* Participation in another research including an exclusion period still in progress at the time of enrollment
* Person placed under guardianship or curatorship or under the protection of justice
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Symbioken
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr Cuylits
Role: PRINCIPAL_INVESTIGATOR
Hôpital Erasme, Bruxelles, BELGIUM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Erasme
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SYMB-SAF1701
Identifier Type: -
Identifier Source: org_study_id